Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hatzl, S; Posch, F; Sareban, N; Stradner, M; Rosskopf, K; Reisinger, AC; Eller, P; Schörghuber, M; Toller, W; Sloup, Z; Prüller, F; Gütl, K; Pilz, S; Rosenkranz, AR; Greinix, HT; Krause, R; Schlenke, P; Schilcher, G.
Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study.
Ann Intensive Care. 2021; 11(1): 73
Doi: 10.1186/s13613-021-00867-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Hatzl Stefan
- Krause Robert
- Co-Autor*innen der Med Uni Graz
- Eller Philipp
- Greinix Hildegard
- Gütl Katharina
- Pilz Stefan
- Posch Florian
- Prüller Florian
- Reisinger Alexander Christian
- Rosenkranz Alexander
- Rosskopf Konrad
- Sareban Nazanin
- Schilcher Gernot
- Schlenke Peter
- Schörghuber Michael
- Sloup Zdenka
- Stradner Martin Helmut
- Toller Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: This study aimed to quantify the potential survival benefit of convalescent plasma therapy (CVP) in critically ill patients with acute respiratory failure related to coronavirus disease-2019 (COVID-19). METHODS: This is a single-center prospective observational cohort study in COVID-19 patients with acute respiratory failure. Immediately after intensive care unit (ICU) admission patients were allocated to CVP treatment following pre-specified criteria to rapidly identify those patients potentially susceptible for this treatment. A propensity score adjustment [inverse probability of treatment weighted (IPTW) analysis] was implemented to account rigorously for imbalances in prognostic variables between the treatment groups. RESULTS: We included 120 patients of whom 48 received CVP. Thirty percent were female with a median age of 66 years [25th-75th percentile 54-75]. Eighty-eight percent of patients presented with severe acute respiratory failure as displayed by a median paO2/FiO2 ratio (Horowitz Index) of 92 [77-150]. All patients required any kind of ventilatory support with more than half of them (52%) receiving invasive ventilation. Thirty-day ICU overall survival (OS) was 69% in the CVP group and 54% in the non-CVP group (log-rank p = 0.049), respectively. After weighing the time-to-event data for the IPTW, the favorable association between CVP and OS became even stronger (log-rank p = 0.035). Moreover, an exploratory analysis showed an overall survival benefit of CVP therapy for patients with non-invasive ventilation (Hazard ratio 0.12 95% CI 0.03-0.57, p = 0.007) CONCLUSION: Administration of CVP in patients with acute respiratory failure related to COVID-19 is associated with improved ICU survival rates.
- Find related publications in this database (Keywords)
- COVID-19
- ICU
- Intensive care
- Convalescent plasma
- Respiratory failure
- Acute respiratory distress syndrome